What American Regent does

American Regent is a US-based specialty pharmaceutical manufacturer of generic and branded sterile injectable drugs, operating as a wholly-owned subsidiary of Japan's Daiichi Sankyo Group since 1991. Founded in 1967 as American Quinine and headquartered in Shirley, New York, the company runs manufacturing facilities in New York and Ohio that have nearly doubled in capacity over recent years, and it maintains a portfolio of FDA-approved injectables spanning IV iron therapy, trace elements for parenteral nutrition, emergency care drugs (epinephrine, atropine, vasopressin), oncology (AB-rated paclitaxel), and a separate animal health franchise built around Adequan and BetaVet equine/canine joint health products. The Iron Franchise — anchored by Venofer (iron sucrose) and Injectafer (ferric carboxymaltose) — supplies the two top-selling IV iron brands in the US and has been the franchise's commercial backbone for roughly 25 years.

The company makes money through wholesale one-time sales of pharmaceutical products to hospitals, home health providers, and veterinary channels, priced via contracts negotiated through Group Purchasing Organizations (GPOs) and delivered through authorized drug wholesalers including ABC, Cardinal, McKesson, and Morris & Dickson. Its primary go-to-market is sales-led, leveraging GPO partnerships (notably the Vizient Novaplus program, where it won the 2023 Program Excellence Award) and direct hospital relationships supported by a Medical Affairs function and a product availability alert system. Commercial operations are organized into three business units: Multisource/Branded Hospital Injectables, the Iron Franchise, and Animal Health. Pipeline expansion has been achieved through in-licensing and acquisition — most notably the 2022 acquisition of HBT Labs for oncology and CNS products, and a 2025 exclusive licensing deal with Allegro NV for Synoglide (up to $35M in milestones) to enter the equine osteoarthritis market.

American Regent does not disclose financial results, but operating signals are consistent with a mid-to-large specialty injectable player: roughly 501–1,000 employees, two US manufacturing sites, near-60-year operating history, leading share in IV iron, a Vizient GPO relationship, NABP accreditation, and a 30+ year-old animal health franchise. The business is structurally dependent on continued FDA approvals, parent-company capital allocation from Daiichi Sankyo, and steady demand from US hospital systems for essential sterile injectables.

Name

American Regent

Legal name

American Regent, Inc.

Website

https://americanregent.com

Company type

Private

Founded year

1967

Operating status

Operating

Headcount range

501–1,000 employees

Short description

American Regent is a US-based specialty pharmaceutical manufacturer and Daiichi Sankyo subsidiary that develops and supplies generic and branded sterile injectable drugs, IV iron therapies, and animal health products to hospitals, GPOs, wholesalers, and veterinary channels.

Ownership category

akta.pro rank

Product category

Specialty Injectable Pharmaceuticals

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Injectable Generics (HLAIABAC)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic injectable pharmaceuticals
• Branded specialty injectables
• IV iron therapy
• Animal health injectables
• Hospital injectable medicines

Headquarters

HQ city

Shirley

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Branded and Generic Injectables: American Regent generates revenue through the sale of branded and generic injectable pharmaceuticals across multiple therapeutic areas including IV additives, anti-inflammatories, and trace elements. The company operates through multiple commercial business units: Multisource and Branded Hospital Injectables, Iron Franchise (Venofer and Injectafer), and Animal Health products (Adequan, BetaVet).
2. Animal Health Products: The animal health division contributes revenue through joint health products for horses and dogs, including Adequan and BetaVet brands.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

American Regent is a US-based specialty pharmaceutical manufacturer that develops, produces, and distributes sterile injectable medicines. Its portfolio spans generic injectables (Atropine Sulfate, Vasopressin, Epinephrine, Sodium/Potassium Phosphates, Paclitaxel, Selenious Acid, Zinc Sulfate), branded products (Venofer, INJECTAFER, Tralement, Multrys), licensed brands (ProvayBlue), and partnered products (Gvoke VialDx), serving hospitals, health systems, and animal health markets.

Product overview

American Regent is a specialty pharmaceutical company and a member of the Daiichi Sankyo Group, focused on developing, manufacturing, and delivering essential sterile injectable medicines. The company operates across multiple commercial business units: (1) Multisource and Branded Hospital Injectables covering IV additives, anti-inflammatories, and trace elements; (2) an Iron Franchise featuring two leading brands—Venofer (iron sucrose injection) and INJECTAFER (ferric carboxymaltose injection)—which together represent the top-selling IV iron therapies in the US; and (3) an Animal Health division anchored by Adequan and BetaVet brands for equine and canine joint health. American Regent's product portfolio spans generic injectables (including Atropine Sulfate, Vasopressin, Epinephrine, Sodium/Potassium Phosphates, Paclitaxel, Selenious Acid, and Zinc Sulfate), licensed brands (ProvayBlue for methemoglobinemia), and partnered products (Gvoke VialDx for hypoglycemia). The company also offers trace element therapies including Tralement and Multrys for parenteral nutrition. Nearly 60 years of operation, American Regent maintains US-based manufacturing facilities and serves healthcare providers and animal health markets.

Differentiator

Problem solved

Functional benefit

Brands

• Adequan: FDA-approved joint health treatment for horses and dogs
• BetaVet
• Adequan Canine

Products and services

• Venofer (iron sucrose injection, USP) Iron replacement therapy for intravenous administration, indicated for the treatment of iron deficiency anemia. It is the #1 selling IV iron in the US and one of the top-selling IV iron brands in the US market.
• INJECTAFER (ferric carboxymaltose injection) Iron replacement therapy for intravenous administration, FDA-approved for treating iron deficiency anemia in adults with intolerance to oral iron or unsatisfactory response, and for adult heart failure patients with reduced ejection fraction. Manufactured under license by American Regent.
• Tralement (trace elements injection 4, USP) First and only FDA-approved multi-trace element injection providing zinc, copper, manganese, and selenium for parenteral nutrition in adult and pediatric patients weighing at least 10 kg.
• Multrys (trace elements injection 4, USP) FDA-approved trace elements injection providing zinc, copper, manganese, and selenium for parenteral nutrition in neonatal and pediatric patients weighing less than 10 kg.
• Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) AB-rated and therapeutically equivalent to Abraxane, reimbursed under J-code J9264. Used for treatment of breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.
• ProvayBlue (methylene blue) Injection, USP FDA-approved methylene blue injection for the treatment of acquired methemoglobinemia in pediatric and adult patients. Licensed trademark of Provepharm Life Solutions, distributed by American Regent.
• Vasopressin Injection, USP FDA-approved injectable indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
• Selenious Acid Injection, USP First and only FDA-approved selenious acid injection for use as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible.
• Epinephrine Injection, USP FDA-approved epinephrine injection available in multiple formulations including 30 mL multiple-dose vial and sulfite-free formulations for emergency cardiac care.
• Sodium Phosphates Injection, USP FDA-approved sodium phosphates injection therapeutically equivalent to reference listed drug, used for parenteral nutrition and electrolyte replacement.
• Potassium Phosphates Injection, USP FDA-approved injectable providing phosphorus and potassium for parenteral nutrition and electrolyte replacement.
• HydrALAZINE Hydrochloride Injection, USP FDA-approved antihypertensive injectable for treatment of hypertensive emergencies.
• Gvoke VialDx (glucagon injection) Glucagon injection for severe hypoglycemia, partnered launch with Xeris Biopharma. FDA-approved for emergency treatment of severe hypoglycemia.
• Atropine Sulfate Injection, USP FDA-approved anticholinergic injectable for bradycardia, bradyarrhythmias, and other uses.
• Papaverine HCL Injection, USP Injectable smooth muscle relaxant for vasodilation and other therapeutic uses.
• Zinc Sulfate Injection, USP Injectable zinc supplement for parenteral nutrition and zinc deficiency treatment.
• American Regent Animal Health Products (Adequan, BetaVet, Synoglide) Veterinary pharmaceutical products including Adequan (polysulfated glycosaminoglycan) for horses and dogs, and BetaVet products for equine care. Synoglide is licensed from Allegro NV for osteoarthritis in horses, planned for US market release in early 2026.

Quantifiable outcome

• Venofer is the #1 selling IV iron in the US
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Allegro NVcoreOEM/ Whitelabel/ Licensing Partner · 25 November 2025American Regent and Allegro NV signed an exclusive licensing deal for Synoglide, a treatment for osteoarthritis in horses. Allegro manufactures the product and American Regent is preparing to introduce it in the US market with planned market release in early 2026. The agreement includes milestone payments up to $35 million and royalties.
• HBT Labs, Inc.coreStrategic or Co-development Partner · 17 August 2022American Regent acquired HBT Labs, Inc., a California-based company specializing in generic and 505(b)(2) pharmaceutical products. The acquisition aims to enhance American Regent's product pipeline, especially in oncology and CNS disorder treatments, and continues the commercialization of HBT's FDA-approved drug applications. HBT Labs subsequently merged into American Regent.
• Xeris Biopharma HoldingscoreStrategic or Co-development PartnerPartnership for FDA approval and U.S. launch of Gvoke VialDx. American Regent collaborated on the regulatory approval and commercialization of this glucagon injection product for hypoglycemic emergency treatment.
• St. John's University College of Pharmacy and Health SciencesminorStrategic or Co-development PartnerPost-doctoral pharmaceutical industry fellowship program providing a two-year fellowship in Medical Affairs with rotation opportunities in other functional areas. The fellow gains experience within American Regent as well as research and teaching opportunities at St. John's University.
• Vizient, Inc.coreGTM or Marketing PartnerAmerican Regent participates in the Vizient Novaplus program, receiving the 2023 Novaplus Program Excellence Award. Vizient is the nation's largest provider-driven health care performance improvement company.
• Daiichi Sankyo, Inc.coreOthersAmerican Regent is a member of the Daiichi Sankyo Group. Paul Diolosa serves as Chairman of the Board, President & CEO. The company operates as part of this global pharmaceutical group.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company with a strong equine and companion animal portfolio. Comparable to American Regent's animal health franchise across joint health, equine therapeutics, and specialty veterinary injectables.
• Viatris: Large global generic and specialty pharmaceutical manufacturer with a meaningful sterile injectable portfolio. Comparable in multisource injectable generics, hospital channel reach, and GPO contracting.
• ICU Medical: Specialty manufacturer of IV therapy and critical care medical devices and pharmaceuticals, including sterile injectables and infusion systems. Comparable in hospital-channel injectable focus and customer base.
• Fresenius Kabi: Global manufacturer of sterile injectable pharmaceuticals (generic IV drugs, infusion solutions, IV iron) and clinical nutrition products. Directly comparable as a major hospital-channel injectable manufacturer competing with American Regent across multisource and branded injectables.
• Hikma Pharmaceuticals: Multinational generic pharmaceutical company with a strong injectable portfolio (Hikma Injectables) sold through US wholesalers and GPOs. Directly competes with American Regent in multisource and specialty injectable generics.
• Zoetis: Global leader in animal health pharmaceuticals and biologics. Directly comparable for American Regent's Animal Health division (Adequan, BetaVet) competing in equine and canine joint health and other veterinary therapeutic areas.
• Amphastar Pharmaceuticals: US-based specialty injectable pharmaceutical manufacturer focused on generic and proprietary injectables, inhalation, and intranasal products. Comparable product categories, hospital-channel GTM, and US manufacturing footprint.

Broad incumbents

• Pfizer (Hospital / Hospira legacy): Through its Hospira legacy, Pfizer operates one of the largest sterile injectable portfolios globally. Overlaps with American Regent across hospital injectables but operates within a much broader branded and generic pharma portfolio.
• B. Braun: Global medical and pharmaceutical company with a sizeable sterile injectable and IV solutions portfolio serving hospitals. Competes in overlapping injectable categories but with a broader medical device and hospital supply footprint.
• Baxter International: Diversified medical products company with significant sterile injectable, IV solutions, and pharmacy compounding offerings. Comparable product overlap in hospital injectables but operates across a wider medical devices and renal portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/americanregent

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Regent